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Clinical and basic experimental evidence indicates that chronic inflammation is the greatest factor in benign
prostatic hyperplasia (BPH) progression, which is the most common cause of Lower Urinary Tract Symptoms
(LUTS). The use of anti-inflammatory agents such as steroids, cyclooxygenase-2 (COX-2) and phytotherapics
have been investigated as forms of treatment for various prostate diseases. Recent evidence has demonstrated that
PDE5 inhibitors (PDE5Is) improve symptoms of BPH/LUTS, possibly as a result of the relaxing of the smooth muscle
fibers of the bladder and prostate by NO/cGMPc signaling, or by improving RhoA/Rho-kinase (ROCK), and
reduction of the hyperactivity of the autonomic nervous system. However, some results have suggested that besides
vasodilatation and their anti-proliferative effect, PDE5Is exert a direct anti-inflammatory effect, by raising cGMP. Given
that inflammation is major factor in benign prostatic hyperplasia (BPH) progression, PDE5Is could act also
restore prostatic function as they act as potent anti-inflammatory drugs. This review aims to provide a
comprehensive summary of the use of phosphodiesterase-5 inhibitors to treat prostatic inflammation.
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The cyclic monophosphate nucleotides cAMP and cGMP
are synthesized by the guanylyl and adenylyl cyclase en-
zymes, respectively. They are recognized as important
second messengers of extracellular signals. Through cyclic
dependent protein kinases, PKA and PKG, control
physiological functions, such as retinal phototransduc-
tion, smooth muscle relaxation, cardiac contractility,
neuroendocrine signals, inhibition of platelet aggregation,
degranulation of neutrophils, and myelogenic inflamma-
tory response [1–5]. The critical role of cAMP and cGMP
in intracellular signaling pathways has identified them as
potential therapeutic targets [6, 7].
Mammalian phosphodiesterases (PDEs) comprise a
large group of enzymes that hydrolyze cAMP and cGMP
to their inactive forms 5′-GMP and 5′-AMP [8, 9]. Eleven
PDE families have been described in order of discovery,
amino acid sequence and catalytic and regulatory charac-
teristics. Some PDEs, such as PDE4 and PDE7 are highly
specific for cAMP hydrolysis, whereas PDE5, PDE6 and* Correspondence: peixoto.christina@gmail.com
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PDE1, PDE2 and PDE3 hydrolyze both nucleotides
[10]. Therefore, inhibitors of PDE (PDEIs) can pro-
long the intracellular action of cAMP and cGMP.
There are potent non-selective PDEi, such as theophi-
line, and others that are specific, such as Rolipram
for PDE4, and Sildenafil, Tadalafil and Vardenafil for
PDE5 [7].
Potent and selective PDE5 inhibitors have been ap-
proved for therapeutic use for the condition of erectile
dysfunction [11] and are currently also being used in
the treatment of pulmonary hypertension [12, 13] and
Raynaud’s phenomenon [14].
cGMP accumulation may inhibit inflammation, and
as such it is a potential tool against the evolution of
diseases in which inflammation plays a central role
[15, 16, 8, 17–19].
Chronic prostatitis is characterized by pelvic and geni-
tourinary pain and lower urinary tract symptoms (LUTS)
that affect frequency and urgency and causes dysuria. Its
precise aethiology remains unclear, although some possi-
bilities include undetectable infection, trauma and im-
munological origin. Therapeutic management includesis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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definitive treatment has been identified [20].
In this way, phosphodiesterase-5 inhibitors may not only
mediate smooth muscle relaxation, but also can directly
reduce prostatic inflammation by increasing cGMP levels.
Phosphodiesterase-5 and inflammation
The nitric oxide (NO) is a highly reactive molecule with
diverse physiological functions [21]. This messenger
plays important roles in the modulation of vascular tone
[22], neurotransmission [23, 24] and the immune system
[25, 26]. NO is formed from L-arginine by NO synthases
(NOS). In addition to the constitutive forms of the en-
zyme, endothelial (eNOS or NOS3) and neuronal
(nNOS ou NOS1), the inducible form (iNOS or NOS2)
is found in activated macrophages and other immune
cells that produce NO in the micromolar range [27]. At
these concentrations, NO induced oxidative DNA dam-
age and modified protein structure and function, which
can lead to cell death. Controversially, eNOS produces
NO at nanomolar concentrations, which have been
documented to have anti-inflammatory actions [28],
which appear to be related directly or indirectly to the
inhibition of the key transcription factor Nuclear Factor
κB (NF-κB) [29, 30].
NO is also the main activator of soluble guanylyl cy-
clase (sGC), an enzyme that synthesizes cGMP. The
level of cGMP is regulated by phosphodiesterases type 5
(PDE5s) enzymes, which break down the phosphodies-
teric bond of cGMP. Several PDE5 inhibitors (PDE5Is)
have been developed and used as therapeutic agents, as
they increase cyclic nucleotide levels by blocking PDE
function, enhancing NO-cGMP signalization [7].
Current concepts based on clinical and experimental
data support a link between endothelial dysfunction and
inflammation, manifested as deficiencies in the production
of NO and prostacyclin [31]. The chronic consequence of
endothelial dysfunction is initiation of vascular diseases.
Sildenafil, the selective PDE5 inhibitor, widely used for
treatment of erectile dysfunction in humans (Viagra®,
Pfizer) has been shown to improve NOS activation of
endothelial cells through ERK signaling [32]. In
addition to increasing NO production by eNOS activa-
tion, Sildenafil also reduces the oxidative stress in-
duced by hyperglicaemia and insulin resistance conditions
[33]. Sildenafil also stimulates eNOS mRNA transcription
in cardiomyocytes, resulting in increased expression
of eNOS, elevated NO generation, guanylyl cyclase ac-
tivation and enhanced GMPc formation [34]. Therefore,
Sildenafil can elevate cGMP in two alternative ways: inhi-
biting PDE5 enzymes and/or inducing mRNA expression
of eNOS.
Interestingly, acute and short-term administration of Sil-
denafil improves endothelial function in men with Type 2diabetes [35], whereas chronic administration of Sildenafil,
besides significantly improving endothelial function, can
also reduce inflammatory markers (nitrite/nitrate levels,
C-reactive protein, IL-6, ICAM-1 and VCAM-1) in pa-
tients with Type 2 diabetes [36]. In addition to improving
endothelial function in patients with coronary arterial dis-
ease and diabetes, and reducing oxidative stress in many
tissues [37, 38], Sildenafil can also normalize endothelial
function and decrease plaque deposition in the aorta in
experimental models of atherosclerosis [39].
Sildenafil has also been shown to be of potential
benefit in the early phases of inflammation and vascu-
lar remodeling in a pulmonary arterial hypertension
(PAH) experimental model. The administration of Silden-
afil following Monocrotaline-induced PAH significantly
reduced the severity of inflammation in the acute stage of
the disease and prevented pulmonary arterial remodeling.
These results suggest that in addition to its vasodilatation
and anti-proliferative effects, Sildenafil has a direct anti-
inflammatory effect [40].
The beneficial effect of the phosphodiesterase-5 inhibi-
tor has been demonstrated in experimental inflammatory
bowel disease (IBD), a relapsing and remitting disease
appearing as a form of ulcerative colitis or Crohn’s disease
with a non-well-known etiology. Treatment of experimen-
tal IBD with Sildenafil reduced markers of oxidative stress
such as myeloperoxidase (MPO) and lipid peroxidation
product (TBARS) significantly, thereby modulating the in-
flammatory response [18]. Recent studies extended and
confirmed the anti-inflammatory effect of PDE5 inhibitor
in a rat model of colitis [41]. Other inhibitors of the PDE
superfamily have been also proposed for IBD treatment,
and PDE4, PDE5 and PDE7 inhibitors seem strong candi-
dates for the next generation of effective drugs [42].
In caecal ligation and puncture (CLP), a model of
polymicrobial sepis, PDE5 markedly attenuated injury
in vital organs such as the kidney and lungs by inhi-
biting proinflammatory cytokine response and ROS
generation [43].
Increased intracellular cGMP levels also lead to the
suppression of colon tumor cell growth and the induc-
tion of apoptosis by activating cGMP dependent pro-
tein kinase (PKG). The COX inhibitory metabolite of
sulindac, sulindac sulfide, as well as several other
NSAIDs, such as indomethacin, meclofenamic acid
and celecoxib, also inhibit PDE5 activity, which is
closely associated to tumor cell growth [44, 45]. Stud-
ies involving human clinical specimens which reported
higher PDE5 levels in colorectal, bladder, lung, and
breast carcinomas than with normal epithelium [46–49]
corroborate these results.
Myeloperoxidase (MPO) level in the blood can be con-
sidered as a marker of endothelial dysfunction and could
be a predictor of cardiovascular disease risk. The oxidation
Peixoto and Gomes Journal of Inflammation  (2015) 12:54 Page 3 of 8of LDL by MPO (MoxLDL) leads to a specific induction
of the inflammatory response, increasing the release of
cytokines such as interleukin 8 (IL-8) and tumor necro-
sis factor alpha (TNF-α) by endothelial cells and mono-
cytes respectively [50]. According to Roumeguère et al
[51] among the three available specific PDE5-Is for
treatment of erectile dysfunction (ED), only tadalafil de-
creased the inflammatory response on endothelial cells
stimulated by myeloperoxidase-modified low-density
lipoprotein (Mox-LDLs) or tumor necrosis factor alpha.
Mox-LDLs have been found in the atherosclerotic
plaque but also in the corpus cavernosum of patients
with ED of vascular origin [51].
Varma et al., [52] proposed that PDE5is have cardio-
protective effects and also could be used to treat insulin
resistance and inflammation. These authors provided
evidence that tadalafil therapy reduced circulating in-
flammatory cytokines in diabetic animal model while im-
proved fasting glucose levels and reduced infarct size
after ischemia-reperfusion injury in the heart [52].
cAMP and cGMP may play a protective role in the
modulation of some inflammatory cell activities of allergic
disorders. Sildenafil inhibits inflammation and airway re-
activity in animal models of airway diseases (asthma and
chronic obstructive pulmonary disease), the effectiveness
of which does not appear to be dependent on endogenous
NO levels [53]. Similarly, vardenafil mimics the effect of
NO by increasing GMPc levels with a subsequent reduc-
tion of histamine release and mast-cell-mediated allergic
reactions [54]. Other studies reported that selective PDE4
inhibitors suppressed hematological and immunological
markers of inflammation and were also effective in redu-
cing specific airway resistance [55, 56].
The PDE5 inhibitors have also muscle and neuro-
protective activities. The administration of sildenafil
after bilateral cavernosal nerve resection preserves
penile corporal smooth muscle and ameliorates fi-
brotic degeneration by down-regulating genes related
to fibrosis and up-regulating genes related to smooth
muscle preservation [57]. At the level of the pelvic
ganglia, sildenafil exerts a neuroprotective effect by
activating neurotrophic factors involved in neuronal
survival and regeneration [58].
Garcia et al., [59] demonstrated that sildenafil can
attenuate inflammation and oxidative stress in damaged
cavernosal nerves by modulating cytokine expression and
promoting a neuroprotective environment that favors
neuron survival. According to such authors, initiation of
the treatment immediately after surgery or even before
radical prostatectomy would produce a better outcome, by
promoting regeneration and functional recovery of the
peripheral nerves [59].
Other studies have shown that the selective PDE5 inhib-
itors raise cGMP levels in the brain and offer protectiveeffects, such as improvement of cognition and memory
[60], reduction of neuronal cell death in ischemic cerebro-
vascular injury [61], reduction of white matter damage
and regulation of inflammatory responses in Multiple
Sclerosis models [62]. Interestingly, Alzheimer’s disease
(AD) has been highly associated with cGMP signaling dys-
function and an ongoing inflammatory process. Zhang
et al., [63] demonstrated that sildenafil prevents neuroin-
flammation, lowers beta-amyloid levels and improves cog-
nitive performance in APP/PS1 transgenic mice, an AD
experimental model [63]. On the other hand, Garcia-
Barroso showed that tadalafil cross the blood-brain barrier
and inhibits PDE5 present in the hippocampus, and that
tadalafil was more effective than sildenafil in attenuating
the phenotypic traits of a mouse model of AD [64].
Results obtained in our laboratory using a multiple
sclerosis (MS) model demonstrated that sildenafil
exerts an effective anti-inflammatory action, greatly
reducing levels of IFN-γ, TNF-α, IL-1β, IL-2 and
cycloxygenase-2 (COX-2), as well as protecting mye-
lin structure. Therefore, the oral administration of
sildenafil can be a possible therapeutic tool for individuals
with MS and other neuroinflammatory/neurodegenerative
diseases, providing additional benefits to those of current
treatments [4].
Phosphodiesterases and prostatic inflammation
Benign prostatic hyperplasia (BPH) is a common cause
of Lower Urinary Tract Symptoms (LUTS), which in-
clude poor urinary stream, urinary hesitancy, a feeling of
incomplete bladder emptying, urgent and/or frequent
urination, and urge incontinence. Approximately 40 % of
men will have BPH by the age of 50, and 80 % by the
age of 80 [65].
Clinical and basic experimental evidence indicates that
chronic inflammation is the major factor in benign pros-
tatic hyperplasia (BPH) progression. Recognition of
prostate secretion products by autoreactive T cells and
animal models on experimental prostatitis demonstrate
an autoimmune component to chronic inflammation.
The close association between activated T cells and stro-
mal cells suggests that these T cells trigger abnormal
growth in the prostate as a result of their specific cyto-
kine production. In BPH, these T cell-derived growth
factors are strongly up-regulated and have been docu-
mented as stimulating stromal growth, matrix formation
and angiogenesis [66]. Consistent with these findings,
the REDUCE clinical trial has shown a relationship be-
tween prostatic inflammation and prostate volume, and
the severity of LUTS [67].
A link between inflammation and prostate proliferative
diseases such as BPH and Prostate Cancer (PCa) has also
been suggested. Inflammatory infiltration is present in
approximately 40 % of cases of patients with BPH, who
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acute urinary retention. Evidence from genetic studies
supports the hypothesis that prostate inflammation may
be a cause of PCa development [68].
In several types of human carcinoma, such as colon
adenocarcinoma, bladder squamous carcinoma and lung
cancers, PDE-5 expression is elevated, suggesting that
these enzymes play a role in controlling cellular prolifer-
ation and apoptosis mechanisms [49, 69]. Additionally,
in human prostate cancer cell lines, studies suggested
that the increase of cAMP and cGMP initiates morpho-
logic differentiation, inhibiting the growth and the inva-
sive potential of these cells [70, 71].
Anti-inflammatory agents, whose effects are promising
in terms of inhibition of cell proliferation [72], have been
analyzed for the treatment of various prostate diseases
such as steroids, cyclooxygenase-2 (COX-2) and phy-
totherapics. In vitro studies also found evidence of the
antiproliferative effect of PDE inhibitors in smooth
muscle cells from human BPH tissue [73, 74].
Preclinical and clinical studies have provided evidence
that PDE5 inhibitors improve symptoms of Benign Pros-
tatic Hyperplasia/Symptoms of Upper Urinary Tract
(BPH/LUTS), possibly as a result of their relaxing action
via NO mechanisms, and inhibition of prostatic stromal
cells proliferation [75–77]. The possible use of PDE5
inhibitors for the treatment of prostate diseases is sup-
ported by the presence of PDE5 in the transition zone of
the prostate, together with PDE4 and PDE11 [8], as well
as the presence of PDE5 in blood vessels and in the
muscular fibers of the bladder and urethra [78].
Several randomized, double-blind, placebo-controlled,
multinational trials have investigated the efficacy and
safety of tadalafil [79–87] or sildenafil [88, 89, 79, 90–92]
in the treatment of BPH-LUTS, as well as in the treatment
of men with ED and with BPH-LUTS, leading to regula-
tory approval in the USA and Europe.
Nonsystematic and systematic reviews have tried to
analyze the role of combined PDE5Is and α-blocker ther-
apy, and have reported a significant improvement in urin-
ary symptoms [76, 92–95]. The most remarkable outcome
from the first systematic review was that the combination
of PDE5Is and α-adrenergic blockers can significantly im-
prove maximum urinary flow rate, compared with only α-
adrenergic blockers, whereas PDE5Is only did not increase
Qmax, compared with placebo [92].
Similarly, a recent systematic review and network meta-
analysis comparing the effectiveness of oral drug therapies
for BPH/LUTS revealed that of all the available drug treat-
ments, combination therapy with α1-adrenoceptor antag-
onists and PDE5 inhibitor ranked highest in efficacy for
decreasing the International Prostate Symptom Score
(IPSS) total score, storage subscore and voiding subscore.
PDE5 inhibitors used alone also had a promising effect,except on maximum flow rate (Qmax). The results sug-
gested that this combination therapy is the most efficient
treatment of LUTS/BPH [96].
In 2010, Eryildirim et al. evaluated the effectiveness
of sildenafil citrate on lower urinary system symptoms
(LUTS) by using symptom score scales, and by ana-
lyzing whether or not the presence of asymptomatic
inflammatory prostatitis altered the symptom scores.
Patients were classified as category IV prostatitis (asymp-
tomatic inflammatory prostatitis) by the presence of sig-
nificant leukocytes (or bacteria or both) in secretion
extracted by prostate massage and urine obtained
after the massage. In cases of LUTS and ED without
asymptomatic inflammatory, sildenafil citrate had an
improving effect on LUTS as well as on ED. However,
in cases with asymptomatic inflammatory prostatitis,
sildenafil citrate did not lead to an improvement in
LUTS [88]. In addition to the limitation of the study,
which did not include a placebo group, was not ran-
domized, and had a small sample size, the absence of
results could be explained by the low number of
PDE5Is doses, which were restricted to 50 mg silden-
afil citrate administered twice a week for 30 days,
ideal for ED treatment but not for chronic inflamma-
tion therapy.
Grimsley et al., proposed a hypothesis to explain the
mechanism of action of sildenafil when ameliorating
prostatitis symptoms. According to the authors these ef-
fects can be explained by the relaxation of the prostatic
duct smooth muscle increasing washout of prostatic re-
flux products [20].
Cantoro et al. [89] evaluated the effectiveness of tam-
sulosin (α-adrenergic blocker) monotherapy versus tam-
sulosin plus sildenafil combination therapy on erectile
dysfunction (ED) in young patients with type III chronic
prostatitis, by using symptom score scales. They ob-
served that tamsulosin monotherapy, as well as a com-
bination therapy (tamsulosin plus sildenafil) had an
improving effect on symptoms and on ED in patients
with type III prostatitis [89].
Whether PDE5Is an effective prostatitis treatment or
not remains controversial. However, it is important to
highlight that until today pre-clinical and clinical studies
have featured doses and short-term treatment, ideal for
ED and BPH/LUTS treatment, not for chronic inflamma-
tion therapy. Although several experimental and clinical
studies have found evidence of their possible benefits, no
chronic treatment with PDE5Is has been performed to
evaluate their effects on the human prostatitis.
It is important also to point out that PDE5Is have been
chronically used as a pharmacological strategy for sev-
eral non-urological disorders, such as pulmonary hyper-
tension, Raynaud’s phenomenon and altitude sickness
[76]. Although PDE5Is are considered safe drugs with
Peixoto and Gomes Journal of Inflammation  (2015) 12:54 Page 5 of 8few side effects, long-term studies are needed to evaluate
their effects on the normal male reproductive system, spe-
cifically on the prostate. The ultrastructural and molecular
analysis realized by our group demonstrated that chronic
treatment of C57Bl/6 mice with sildenafil 25 mg/kg for
4 weeks enhanced prostatic glandular activity, however,
no differences were observed in sGC, eNOS, PSA and
TGF-β expression [97]. These results suggested that the
chronic use of sildenafil does not cause evident pros-
tatic damage, and therefore, seems safe for the treat-
ment of a variety of disorders.
Recent studies have demonstrated that BPH/LUTS,
prostatic cancer and metabolic syndrome (MetS) are
often associated with one another [98]. Metabolic syn-
drome (MetS) is a complex of clustering metabolic ab-
normalities and comprises a number of disorders such
as insulin resistance, hypertension and obesity, which all
act as known risk factors for erection dysfunction (ED).
Interestingly, some studies have shown that treatment
with PDE5Is, in addition to relaxing the muscular wall,
may positively affect low urinary tract blood perfusion,
restoring function and causing morphologic changes in
the bladder and prostate induced by chronic pelvic is-
chemia caused by MetS or hypertension [99, 100]. In
spontaneous hypertensive rats, chronic treatment with
tadalafil or other PDE5Is counteracted all LUTS alter-
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all been associated with increased sympathetic activity
via enhanced glucose metabolism. This process pro-
motes the activity of α-adrenergic receptors, increas-
ing the smooth muscle tone of the male genitourinary
tract [102, 103]. Insulin-like growth factor-1 (IGF-1)
contributes to the development and progression of
BPH/LUTS. Since these molecules have a similar
structure, insulin can bind to IGF-1 receptors and ac-
tivate the signaling pathway for the growth and prolif-
eration of epithelial and stromal prostatic cells [104].
Therefore, PDE5Is could be used as pharmacological
tools for the treatment of ED, LUTS/BPH and
chronic pelvic ischemia by smooth muscle relaxation
via cGMP-dependent RhoA/Rho-kinase (ROCK) sig-
naling inhibition [105–108], and possibly by reducing
autonomic hyperactivity, which is a component of the
metabolic syndrome [109].
Moreover, chronic inflammation has also been claimed
to be one of the putative links between MetS and BPH/
LUTS. Recently, Vignozzi et al. [110] demonstrated that
the PDE5 blockade exerts anti-inflammatory effects on
human myofibroblast prostatic cells, blunting inflamma-
tory and metabolic insults. These authors showed that
treatment with tadalafil or vardenafil suppressed IL-8
and IP-10 secretion induced by inflammatory (TNF-α)
and metabolic (oxLDL, AGE and IGF-1) stimuli. PDE5Is










odiesterase 5 Inhibitors (PDE5Is) on prostatic inflammmation. PDE5Is
y inducing high levels of cGMP
Peixoto and Gomes Journal of Inflammation  (2015) 12:54 Page 6 of 8to-myofibroblast transdifferentiation and tissue remodel-
ling marker genes, most likely via the activation of
cGMP/PKG signaling [110].
Conclusion
PDE5Is are therapeutical tools used for several urological
and non-urological disorders, and experimental evidence
suggest that their chronic use does not induce cellular
and molecular prostatic alterations. The mechanisms in-
volved in improvements observed in BPH/LUTS possibly
include relaxation of the smooth muscles of the bladder
and prostate by NO/cGMPc signaling or via improving
RhoA/Rho-kinase (ROCK), and by reduction of the
hyperactivity of the autonomic nervous system. PDE5Is
can also direct and indirectly down-regulate prostatic in-
flammation/BPH/LUTS by inducing high levels of cGMP
(Fig. 1). In conclusion, since inflammation is a major fac-
tor in benign prostatic hyperplasia (BPH) progression,
PDE5Is could also restore prostatic function, as they act
as potent anti-inflammatory drugs.
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